guest ::
| Home > Publications Database > Quantitative and qualitative tremor evaluation after MR-guided focused ultrasound thalamotomy. > print |
| Home > Publications Database > Quantitative and qualitative tremor evaluation after MR-guided focused ultrasound thalamotomy. > print |
| 001 | 278790 | ||
| 005 | 20250604100730.0 | ||
| 024 | 7 | _ | |a 10.3389/fneur.2025.1594382 |2 doi |
| 024 | 7 | _ | |a pmid:40386019 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12081243 |2 pmc |
| 037 | _ | _ | |a DZNE-2025-00626 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Purrer, Veronika |0 P:(DE-2719)9000867 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Quantitative and qualitative tremor evaluation after MR-guided focused ultrasound thalamotomy. |
| 260 | _ | _ | |a Lausanne |c 2025 |b Frontiers Research Foundation |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1748939212_16670 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Tremor syndromes are common neurological disorders, usually distinguished by clinical examination. Ordinal rating scales are widely used to rate tremor severity but are limited by subjective observation, interrater reliability, ceiling effects and lack of knowledge about sensitivity to change emphasizing the relevance of quantitative methods.To assess tremor characteristics in essential tremor (ET) and Parkinson's disease tremor (PT) quantitatively, we used a wearable triaxial accelerometer in comparison to a common clinical rating scale. Furthermore, different activation conditions and changes after treatment with MR-guided focused ultrasound (MRgFUS) were examined concomitantly. Patients with disabling, medication-refractory ET (n = 35) or PT (n = 21) undergoing unilateral MRgFUS thalamotomy were assessed before, 1, 6 and 12 months after MRgFUS treatment. Clinical assessments included the Clinical Rating Scale for Tremor (CRST) and accelerometric recordings at rest, posture and kinetic movement. Peak frequencies (fp), frequency width at half maximum (FWHM), tremor stability index (TSI), and half-width power (HWP) were extracted from the power spectrum of acceleration and compared to the CRST.We observed moderate to strong correlations between CRST subscores and log-transformed HWP, whereas significant correlations were only evident in ET when groups were evaluated separately. Fp, FWHM and TSI showed no differences between groups and conditions. Further, repeated measurements after MRgFUS treatment revealed significant changes of tremor severity in both, clinical rating and accelerometric recordings.Tremor assessment using accelerometric recordings provided a fast and investigator independent method for tremor characterization and quantitative assessment, which were sensitive to changes after therapeutic interventions. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a MRgFUS |2 Other |
| 650 | _ | 7 | |a accelerometry |2 Other |
| 650 | _ | 7 | |a quantitative measurements |2 Other |
| 650 | _ | 7 | |a thalamotomy |2 Other |
| 650 | _ | 7 | |a tremor |2 Other |
| 700 | 1 | _ | |a Chand, Tara |b 1 |
| 700 | 1 | _ | |a Pohl, Emily |0 P:(DE-2719)9003337 |b 2 |u dzne |
| 700 | 1 | _ | |a Weiland, Hannah |b 3 |
| 700 | 1 | _ | |a Borger, Valeri |b 4 |
| 700 | 1 | _ | |a Schmeel, Carsten |b 5 |
| 700 | 1 | _ | |a Boecker, Henning |0 P:(DE-2719)2810726 |b 6 |u dzne |
| 700 | 1 | _ | |a Wüllner, Ullrich |0 P:(DE-2719)2000056 |b 7 |e Last author |u dzne |
| 773 | _ | _ | |a 10.3389/fneur.2025.1594382 |g Vol. 16, p. 1594382 |0 PERI:(DE-600)2564214-5 |p 1594382 |t Frontiers in neurology |v 16 |y 2025 |x 1664-2295 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/278790/files/DZNE-2025-00626.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/278790/files/DZNE-2025-00626.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:278790 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000867 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 2 |6 P:(DE-2719)9003337 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2810726 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2000056 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-07 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT NEUROL : 2022 |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-01-11T07:34:54Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-01-11T07:34:54Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-07 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-07 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2025-01-07 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-01-11T07:34:54Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-07 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-07 |
| 920 | 1 | _ | |0 I:(DE-2719)1011302 |k AG Wüllner |l Biomarker Parkinson's Disease |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1011001 |k Clinical Research (Bonn) |l Clinical Research Coordination |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1011202 |k AG Boecker |l Positron Emissions Tomography (PET) |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1011302 |
| 980 | _ | _ | |a I:(DE-2719)1011001 |
| 980 | _ | _ | |a I:(DE-2719)1011202 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|